{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:06:45Z","timestamp":1790165205336,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Sarcopenic obesity (SO), the coexistence of excess adiposity with low skeletal muscle mass and function, is a growing but frequently underdiagnosed condition associated with physical disability, cardiometabolic disease, and increased mortality. Its recognition is hampered by an over-reliance on body mass index, which conceals muscle depletion, and by consensus diagnostic pathways that identify SO only once measurable functional impairment has developed. Advances in body-composition imaging and molecular biology may enable detection of subclinical abnormalities not captured by conventional anthropometric or functional assessment. This narrative review examines the phenotypic and circulating biomarkers proposed for the identification and characterization of SO. It first considers phenotypic markers of muscle quantity and, increasingly, muscle quality including myosteatosis quantified by computed tomography and the bioelectrical phase angle. It then surveys the molecular landscape: myokines and adipokines (myostatin, irisin, the leptin-to-adiponectin ratio), inflammatory mediators (such as tumor necrosis factor-\u03b1 and interleukin-6) that drive anabolic resistance, and emerging metabolomic, lipidomic, and microRNA signatures. Drawing these together, we propose an integrated phenotype\u2013biomarker framework for precision risk characterization, and consider its relevance in the era of highly effective pharmacological weight loss, where muscle preservation has become an urgent priority. Although most molecular markers remain investigational and lack standardized cut-offs, their integration with phenotypic assessment offers a promising route toward earlier, individualized identification of SO; assay standardization and prospective validation are the principal priorities for translation. The proposed framework is conceptual and has not been prospectively validated.<\/jats:p>","DOI":"10.3389\/fnut.2026.1930821","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:50:24Z","timestamp":1790164224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond body mass index: phenotypic and circulating biomarkers for the identification and characterization of sarcopenic obesity"],"prefix":"10.3389","volume":"13","author":[{"given":"Maha","family":"Al Turki","sequence":"first","affiliation":[{"name":"Department of Clinical Nutrition, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Centre, National Guard Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-023-00943-z","article-title":"Sarcopenic obesity in older adults: a clinical overview","volume":"20","author":"Prado","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1185221","DOI":"10.3389\/fendo.2023.1185221","article-title":"Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management","volume":"14","author":"Wei","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1016\/j.clnu.2021.06.009","article-title":"Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis","volume":"40","author":"Gao","year":"2021","journal-title":"Clin Nutr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12877-024-04952-z","article-title":"Prevalence of sarcopenic obesity in the older non-hospitalized population: a systematic review and meta-analysis","volume":"24","author":"Luo","year":"2024","journal-title":"BMC Geriatr"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41430-024-01551-4","article-title":"Myosteatosis is associated with adiposity, metabolic derangements and mortality in patients with chronic kidney disease","volume":"79","author":"Sabatino","year":"2025","journal-title":"Eur J Clin Nutr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1366229","DOI":"10.3389\/fendo.2024.1366229","article-title":"Sarcopenic obesity prevalence and diagnostic agreement according to the 2022 ESPEN and EASO consensus in hospitalized older adults with severe obesity","volume":"15","author":"Danielewicz","year":"2024","journal-title":"Front Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101530","DOI":"10.1016\/j.arr.2021.101530","article-title":"Biomarkers shared by frailty and sarcopenia in older adults: a systematic review and meta-analysis","volume":"73","author":"Picca","year":"2022","journal-title":"Ageing Res Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.3390\/ijms26115113","article-title":"Pathophysiological mechanisms underlying sarcopenia and sarcopenic obesity: a systematic review and meta-analysis of biomarker evidence","volume":"26","author":"Feng","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3390\/life15121911","article-title":"Advancing precision diagnosis of sarcopenic obesity through digital technologies, wearables and omics data","volume":"15","author":"Panagiotou","year":"2025","journal-title":"Life"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"21799","DOI":"10.1038\/s41598-024-72420-0","article-title":"Relative muscle indices and healthy reference values for sarcopenia assessment using T10 through L5 computed tomography skeletal muscle area","volume":"14","author":"Derstine","year":"2024","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e172319","DOI":"10.1001\/jamaoncol.2017.2319","article-title":"Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer","volume":"3","author":"Cespedes Feliciano","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/jcsm.12860","article-title":"Phase angle from bioelectrical impedance analysis is a useful indicator of muscle quality","volume":"13","author":"Akamatsu","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"173.e17","DOI":"10.1016\/j.jamda.2014.10.024","article-title":"The bioimpedance phase angle predicts low muscle strength, impaired quality of life, and increased mortality in old patients with cancer","volume":"16","author":"Norman","year":"2015","journal-title":"J Am Med Dir Assoc"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"28629","DOI":"10.1038\/s41598-024-79534-5","article-title":"Myostatin as a plausible biomarker for early stage of sarcopenic obesity","volume":"14","author":"Ishibashi","year":"2024","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/gerona\/gly255","article-title":"Relationship of circulating growth and differentiation factors 8 and 11 and their antagonists as measured using liquid chromatography-tandem mass spectrometry with age and skeletal muscle strength in healthy adults","volume":"74","author":"Semba","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e70172","DOI":"10.1002\/jcsm.70172","article-title":"Cross-sectional and longitudinal associations of irisin and adiponectin with obesity, sarcopenia and sarcopenic obesity","volume":"17","author":"Kim","year":"2026","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e26529","DOI":"10.1097\/MD.0000000000026529","article-title":"Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: a cross-sectional study","volume":"100","author":"Oguz","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s41999-024-01097-5","article-title":"Circulating irisin levels in patients with sarcopenia: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Eur Geriatr Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/cells9091970","article-title":"Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy","volume":"9","author":"Yoshida","year":"2020","journal-title":"Cells"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1152\/physrev.90100.2007","article-title":"Muscle as an endocrine organ: focus on muscle-derived interleukin-6","volume":"88","author":"Pedersen","year":"2008","journal-title":"Physiol Rev"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cmet.2009.02.002","article-title":"A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance","volume":"9","author":"Newgard","year":"2009","journal-title":"Cell Metab"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrendo.2014.171","article-title":"Branched-chain amino acids in metabolic signalling and insulin resistance","volume":"10","author":"Lynch","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.plipres.2005.11.002","article-title":"Ceramides in insulin resistance and lipotoxicity","volume":"45","author":"Summers","year":"2006","journal-title":"Prog Lipid Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jcsm.12227","article-title":"Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine","volume":"9","author":"Siracusa","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/jcsm.12878","article-title":"MicroRNAs in obesity, sarcopenia, and commonalities for sarcopenic obesity: a systematic review","volume":"13","author":"Dowling","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jamda.2013.05.021","article-title":"Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group","volume":"14","author":"Bauer","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.clnu.2014.04.007","article-title":"Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN expert group","volume":"33","author":"Deutz","year":"2014","journal-title":"Clin Nutr"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clnu.2018.05.024","article-title":"ESPEN guideline on clinical nutrition and hydration in geriatrics","volume":"38","author":"Volkert","year":"2019","journal-title":"Clin Nutr"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s13539-012-0078-2","article-title":"Biomarkers of sarcopenia in clinical trials - recommendations from the international working group on sarcopenia","volume":"3","author":"Cesari","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/jcsm.12051","article-title":"Biomarkers for physical frailty and sarcopenia: state of the science and future developments","volume":"6","author":"Calvani","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1186\/s12967-025-06575-3","article-title":"Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: an umbrella review","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1930821\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:50:25Z","timestamp":1790164225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1930821\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":36,"alternative-id":["10.3389\/fnut.2026.1930821"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1930821","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1930821"}}